JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on February 18, 2005; DOI: 10.1124/jpet.104.080713


0022-3565/05/3132-877-887$20.00
JPET 313:877-887, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.080713v1
313/2/877    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McCollum, G.
Right arrow Articles by McCabe, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McCollum, G.
Right arrow Articles by McCabe, M. J., Jr.

CELLULAR AND MOLECULAR

Arsenite Delays Progression through Each Cell Cycle Phase and Induces Apoptosis following G2/M Arrest in U937 Myeloid Leukemia Cells

Geniece McCollum, Peter C. Keng, J. Christopher States, and Michael J. McCabe, Jr.

Departments of Environmental Medicine (G.M., M.J.M.) and Radiation Oncology (P.C.K.), School of Medicine and Dentistry, University of Rochester, Rochester, New York; and Department of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky (J.C.S.)

Arsenic is a well known toxicant and carcinogen that is also effective as a chemotherapeutic in the treatment of acute promyelocytic leukemia. Although its effects on humans are well documented, arsenic's mechanism of action is not well understood. Its ability to act as a carcinogen and as a chemotherapeutic seems paradoxical. However, cancer cell transformation and cancer cell destruction can both occur through perturbations of the cell cycle machinery, making cell cycle function a likely target of arsenic action. Arsenic has previously been shown to inhibit cancer cell cycle progression, but the targeted cell cycle phase has been debated. This study was designed to identify the cell cycle phase at which U937 cells are most sensitive to arsenite-induced growth inhibition. Centrifugal elutriation was used to divide asynchronous cell cultures into specific cell cycle phase-enriched fractions. These fractions were monitored for cell cycle phase progression in the presence and absence of sodium arsenite. We found an overall reduction in cell cycle progression rather than induction of arrest at one specific checkpoint. G2/M is the phase most sensitive to arsenite-induced apoptosis. However, arsenite profoundly affects U937 cell growth by increasing the length of time it takes cells to transit each phase of the cell cycle. Future study of cell cycle inhibition by arsenic should consider that the effect may not be mediated by the major cell cycle checkpoints. Arsenic's ability to inhibit growth in any cell cycle phase may increase its value as a chemotherapeutic used together with other, more phase-selective agents, such as camptothecin.


Received November 12, 2004; accepted February 17, 2005.

Address correspondence to: Dr. Michael J. McCabe, Jr., Department of Environmental Medicine, University of Rochester School of Medicine and Dentistry, 575 Elmwood Ave., Rochester, NY 14642. E-mail: michael_mccabe{at}urmc.rochester.edu




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
X. Wu, M. Yamada-Mabuchi, E. J. Morris, P. S. Tanwar, L. Dobens, S. Gluderer, S. Khan, J. Cao, H. Stocker, E. Hafen, et al.
The Drosophila homolog of human tumor suppressor TSC-22 promotes cellular growth, proliferation, and survival
PNAS, April 8, 2008; 105(14): 5414 - 5419.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
K. Nohara, K. Ao, Y. Miyamoto, T. Suzuki, S. Imaizumi, Y. Tateishi, S. Omura, C. Tohyama, and T. Kobayashi
Arsenite-Induced Thymus Atrophy is Mediated by Cell Cycle Arrest: A Characteristic Downregulation of E2F-Related Genes Revealed by a Microarray Approach
Toxicol. Sci., February 1, 2008; 101(2): 226 - 238.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
G. M. Lehmann and M. J. McCabe Jr
Arsenite Slows S Phase Progression via Inhibition of cdc25A Dual Specificity Phosphatase Gene Transcription
Toxicol. Sci., September 1, 2007; 99(1): 70 - 78.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
X. Shi, A. Seluanov, and V. Gorbunova
Cell Divisions Are Required for L1 Retrotransposition
Mol. Cell. Biol., February 15, 2007; 27(4): 1264 - 1270.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
B. F. Taylor, S. C. McNeely, H. L. Miller, G. M. Lehmann, M. J. McCabe Jr., and J. C. States
p53 Suppression of Arsenite-Induced Mitotic Catastrophe Is Mediated by p21CIP1/WAF1
J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 142 - 151.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.